Archive | GlycoMimetics

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]

Comments Off on GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Continue Reading →

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →

PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast

King-Rachel-PVcom-FeaturedImage630x315-560x315

Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”

Comments Off on PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast Continue Reading →

GlycoMimetics, Inc. Co-Founder & CEO Rachel K. King Interviewed on New Episode of BHI Podcast – BioTalk with Rich Bendis

MVIMG_20180215_144308 square

Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. (GMI), joins Rich Bendis for the latest episode of BioTalk. They cover topics from her background in the industry to running a publicly traded company in the BioHealth Capital Region. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the […]

Comments Off on GlycoMimetics, Inc. Co-Founder & CEO Rachel K. King Interviewed on New Episode of BHI Podcast – BioTalk with Rich Bendis Continue Reading →